Analysis of two pharmacodynamic biomarkers using acoustic micro magnetic particles on the ViBE bioanalyzer

Yan, Zhao; Madison, Lara L.; Burkhardt, Anne L.; Yu, Jie; Tayber, Olga; Li, Zhi; Wu, Dongyun; Loke, Huay-Keng; Wysong, Deborah R.; Iartchouk, Natalia; Smith, Michael D.; Kuranda, Mike; Li, Ping; Bembenek, Michael E.

doi:10.1016/j.ab.2010.11.012

Cited by 11 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mouse plasma CA125 levels were measured via a custom assay using BioScale’s Acoustic Membrane Micro Particle (AMMP) technology (18). Universal Detection Kit, diluent, regeneration solution, and magnetic beads were purchased from BioScale, and complementary detection and capture antibodies were purchased from CalBioreagents (Cat# M184 and M185).…”

Section: Methodsmentioning

confidence: 99%

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

Liu

Palakurthi

Zeng

et al. 2017

Clinical Cancer Research

110

118

View full text Add to dashboard Cite

Purpose Ovarian cancer is the leading cause of death from gynecologic malignancy in the United States, with high rates of recurrence and eventual resistance to cytotoxic chemotherapy. Model systems that allow for accurate and reproducible target discovery and validation are needed to support further drug development in this disease. Experimental Design Clinically-annotated patient-derived xenograft (PDX) models were generated from tumor cells isolated from the ascites or pleural fluid of patients undergoing clinical procedures. Models were characterized by immunohistochemistry and by molecular analyses. Each PDX was luciferized to allow for reproducible in vivo assessment of intraperitoneal tumor burden by bioluminescent imaging (BLI). Plasma assays for CA125 and human LINE-1 were developed as secondary tests of in vivo disease burden. Results 14 clinically annotated and molecularly characterized luciferized ovarian PDX models were generated. Luciferized PDX models retain fidelity to both the non-luciferized PDX and the original patient tumor, as demonstrated by immunohistochemistry, array CGH, and targeted and whole-exome sequencing analyses. Models demonstrated diversity in specific genetic alterations and activation of PI3K signaling pathway members. Response of luciferized PDX models to standard of care therapy could be reproducibly monitored by BLI or plasma markers. Conclusions We describe the establishment of a collection of 14 clinically annotated and molecularly characterized luciferized ovarian PDX models in which orthotopic tumor burden in the intraperitoneal space can be followed by standard and reproducible methods. This collection is well-suited as a platform for proof-of-concept efficacy and biomarker studies and for validation of novel therapeutic strategies in ovarian cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

Liu

Palakurthi

Zeng

et al. 2017

Clinical Cancer Research

110

118

View full text Add to dashboard Cite

show abstract

“…The use of immunomagnetic beads also provides a modular platform for assay development since the beads can be functionalized with the appropriate reagents in order to replicate the ELISA protocols (Bielefeld‐Sevigny, 2009). Assay kits using such beads and development platforms are commercially available (Dickerson et al, 2011; Yan et al, 2011). Modular and automated platforms using microfluidic based protein microarrays (Bioaffy™ and Gyrolab™ xP workstation; Gyros AB, Uppsala, Sweden) and biosensors (Dip and Read™ and Octet® system; Forte Bio, Inc., CA, Menlo Park) are also available.…”

Section: Resultsmentioning

confidence: 99%

Identifying analytics for high throughput bioprocess development studies

Konstantinidis

Kong

Titchener‐Hooker

2013

Biotech & Bioengineering

View full text Add to dashboard Cite

In recent years, high throughput screening (HTS) studies have been increasingly employed as an integral element of bioprocess development activities. These studies are often limited by an analytical bottleneck; they generate multiple samples for analysis and the available analytical methods cannot always cope with the added analytical burden. A potential solution to this challenge is offered by the deployment of appropriate analytics. This article outlines features of analytical methods that affect their fit to high throughput (HT) applications. These are discussed for a range of analytics frequently used in bioprocess development studies of monoclonal antibodies. It then outlines how these features need to be considered in order to classify analytical methods in terms of their particular application in high throughput scenarios.

show abstract

“…Due to this, the assay would have been implemented only if the drug's efficacious dose would have been found to be lower than actual. Other published data also suggests that the narrow range might be a limitation of the technology (6,7).…”

Section: Discussionmentioning

confidence: 99%

“…(5) The magnet is removed and all unbound reagents are washed away leaving only the bound immunocomplex. (6) The change in vibrating frequency is measured ( Fig. 1a) [www.bioscale.com].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Acoustic Membrane Microparticle (AMMP) Technology for a Sensitive Ligand Binding Assay to Support Pharmacokinetic Determinations of a Biotherapeutic

Chilewski

Dickerson

Mora

et al. 2014

AAPS J

View full text Add to dashboard Cite

Abstract. Achieving the required sensitivity can be a challenge in the development of ligand binding assays for pharmacokinetic (PK) determinations of biotherapeutics. To address this need, BioScale's Acoustic Membrane Microparticle (AMMP) technology was evaluated for the quantification of a PEGylated domain antibody (dAb) biotherapeutic. Previous uses of this technology had shown utility in biomarker and process development applications and this is the first application, to our knowledge, for PK determinations. In this evaluation, AMMP was capable of delivering a sensitivity of 0.750 ng/mL, which surpasses the sensitivity requirements for the majority of assays to support PK determinations. This evaluation demonstrates that this emerging technology has the ability to produce the required sensitivity, reproducibility, and selectivity needed to meet the industry's standards for PK analysis.

show abstract

Analysis of two pharmacodynamic biomarkers using acoustic micro magnetic particles on the ViBE bioanalyzer

Cited by 11 publications

References 7 publications

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

Identifying analytics for high throughput bioprocess development studies

Evaluation of Acoustic Membrane Microparticle (AMMP) Technology for a Sensitive Ligand Binding Assay to Support Pharmacokinetic Determinations of a Biotherapeutic

Contact Info

Product

Resources

About